

URGENT: State Delays Medi-Cal Rx Transition until April, Provider Trainings Available

Effective April 1, 2021, Medi-Cal pharmacy benefits will transition from plans like CenCal Health back to the State. As a result, the State has contracted with Magellan to administer the pharmacy benefit, referred to as “Medi-Cal Rx.”



This delay gives pharmacy providers and prescribers time to be prepared for this transition.

In preparation of the pharmacy carve-out, DHCS has created a Medi-Cal Rx website to answer frequently asked questions, including:

- What is Medi-Cal Rx?
- What Medi-Cal Managed Care Plans are and are not impacted by Medi-Cal Rx?
- What will not change as part of Medi-Cal Rx?

To read the answers to these questions and more, please visit dhcs.ca.gov/provgovpart/pharmacy/Pages/Medi-CalRX.aspx.

DHCS is also providing training on their new Medi-Cal Rx website at medi-calrx.dhcs.ca.gov/home/education/.

To access these sessions, you will first need to register with the User Administration Console (UAC) at uac.magellanrx.com/.

To view a complete list of upcoming training sessions, please visit:

- **Pharmacy Providers:** medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/education-and-outreach/2020.11_EOT_Medi-Cal_Rx_Web_Portal_Training_Schedule_ONLY.pdf
- **Prescribers:** medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/education-and-outreach/2020.11_EOT_Medi-Cal_Rx_Web_Portal_Training_Schedule_ONLY.pdf

We recommend all providers sign up for program updates at <https://mcrxsspages.dhcs.ca.gov/Medi-CalRxDHCSgov-Subscription-Sign-Up>.

View our 2020 Community Report! CenCal2020.org



Beginning 1/1/21: CenCal Health to Prefer Select Biosimilar Products

Effective **January 1, 2021**, CenCal Health will prefer select biosimilar products over their reference products. This determination is consistent with the enabling statute of the Medi-Cal program found in title 22 around the provision of the lowest cost medically necessary service as well as the unanimous adoption by the network physicians and pharmacists at the August 2020 CenCal Health Pharmacy & Therapeutics Committee meeting.



CenCal Health's preferred biosimilars will be for the following physician administered drugs:

Procedure Code	Drug Description
<u>Preferred Biosimilar</u> Q5107 Q5118 <u>Non-Preferred Reference Product</u> J9035	INJECTION, BEVACIZUMAB-AWWB, BIOSIMILAR (MVASI), 10 MG INJECTION, BEVACIZUMAB-BVZR, BIOSIMILAR, (ZIRABEV), 10 MG INJECTION, BEVACIZUMAB, (AVASTIN, IMURON), 10mg
<u>Preferred Biosimilar</u> Q5117 Q5116 <u>Non-Preferred Reference Product</u> J9355	INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG INJECTION, TRASTUZUMAB-QYYP, BIOSIMILAR, (TRAZIMERA), 10 MG INJECTION, TRASTUZUMAB, (HERCEPTIN), 10MG

All affected codes will remain as TAR required, but the preferred biosimilar products must be tried and failed before consideration of coverage of the reference product. The biosimilar products are not interchangeable with the reference product, and will require new orders. Biosimilar products are highly similar, and have no clinically meaningful differences from an existing FDA-approved reference product.

If you have questions or need additional information, please contact CenCal Health Pharmacy department at (805) 562-1080.